Display options
Cite
Hussain HA, Harvey AJ. Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol. 2014;5(3):299-310doi: 10.5306/wjco.v5.i3.299.
Hussain, H. A., & Harvey, A. J. (2014). Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy. World journal of clinical oncology, 5(3), 299-310. https://doi.org/10.5306/wjco.v5.i3.299
Hussain, Haroon A, and Harvey, Amanda J. "Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy." World journal of clinical oncology vol. 5,3 (2014): 299-310. doi: https://doi.org/10.5306/wjco.v5.i3.299
Hussain HA, Harvey AJ. Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol. 2014 Aug 10;5(3):299-310. doi: 10.5306/wjco.v5.i3.299. PMID: 25114846; PMCID: PMC4127602.
Copy Download .nbib Format: NLM
Share it on

World J Clin Oncol. 2014 Aug 10;5(3):299-310. doi: 10.5306/wjco.v5.i3.299.

Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

World journal of clinical oncology

Haroon A Hussain, Amanda J Harvey

Affiliations

  1. Haroon A Hussain, Amanda J Harvey, Brunel Institute for Cancer Genetics and Pharmacogenomics, Biosciences, Brunel University (London), Uxbridge UB8 3PH, United Kingdom.

PMID: 25114846 PMCID: PMC4127602 DOI: 10.5306/wjco.v5.i3.299

Abstract

There have been significant improvements in the detection and treatment of breast cancer in recent decades. However, there is still a need to develop more effective therapeutic techniques that are patient specific with reduced toxicity leading to further increases in patients' overall survival; the ongoing progress in understanding recurrence, resistant and spread also needs to be maintained. Better understanding of breast cancer pathology, molecular biology and progression as well as identification of some of the underlying factors involved in breast cancer tumourgenesis and metastasis has led to the identification of novel therapeutic targets. Over a number of years interest has risen in breast tumour kinase (Brk) also known as protein tyrosine kinase 6; the research field has grown and Brk has been described as a desirable therapeutic target in relation to tyrosine kinase inhibition as well as disruption of its kinase independent activity. This review will outline the current "state of play" with respect to targeted therapy for breast cancer, as well as discussing Brk's role in the processes underlying tumour development and metastasis and its potential as a therapeutic target in breast cancer.

Keywords: Breast neoplasms; Breast tumour kinase; Intracellular signaling peptides and proteins; Protein kinase inhibitors; Protein tyrosine kinase 6; Targeted molecular therapy

References

  1. Oncogene. 1994 Aug;9(8):2383-90 - PubMed
  2. Oncogene. 2000 Aug 31;19(37):4273-82 - PubMed
  3. Proc Natl Acad Sci U S A. 1986 Dec;83(23):8819-23 - PubMed
  4. Oncogenesis. 2012 May 07;1:e11 - PubMed
  5. Cell Signal. 2008 Feb;20(2):432-42 - PubMed
  6. Oncogene. 2003 Aug 7;22(32):5006-10 - PubMed
  7. Mol Cancer Ther. 2012 Nov;11(11):2311-20 - PubMed
  8. Front Oncol. 2013 Sep 23;3:250 - PubMed
  9. Int J Cancer. 2001 Dec 15;94(6):774-82 - PubMed
  10. J Cell Sci. 2001 Apr;114(Pt 7):1253-63 - PubMed
  11. Oncogene. 2013 Sep 5;32(36):4304-12 - PubMed
  12. J Pharmacol Exp Ther. 2005 Dec;315(3):971-9 - PubMed
  13. Oncogene. 2005 Aug 25;24(36):5656-64 - PubMed
  14. Oncogene. 2004 Mar 18;23(12):2216-23 - PubMed
  15. Clin Cancer Res. 2002 Feb;8(2):361-7 - PubMed
  16. BMC Cell Biol. 2009 Oct 31;10:78 - PubMed
  17. Tumour Biol. 2011 Oct;32(5):873-80 - PubMed
  18. Cell. 2006 Nov 3;127(3):469-80 - PubMed
  19. J Biomol NMR. 2001 Mar;19(3):291-2 - PubMed
  20. Cancer Res. 2001 Sep 1;61(17):6583-91 - PubMed
  21. Mol Pharmacol. 2007 Aug;72(2):248-58 - PubMed
  22. Cancer Res. 2004 Jan 1;64(1):286-91 - PubMed
  23. Oncogene. 2012 Oct 4;31(40):4372-83 - PubMed
  24. Br J Cancer. 2007 Mar 12;96(5):801-7 - PubMed
  25. Cancer Res. 2001 Oct 1;61(19):7196-203 - PubMed
  26. Cancer Res. 2004 Jun 1;64(11):3981-6 - PubMed
  27. Cancer Res. 2004 Sep 15;64(18):6652-9 - PubMed
  28. Oncogene. 2006 Aug 10;25(35):4904-12 - PubMed
  29. Cancer Res. 2008 Oct 1;68(19):7779-87 - PubMed
  30. Cell Signal. 2013 Sep;25(9):1754-61 - PubMed
  31. Biochem Biophys Res Commun. 2013 Feb 22;431(4):734-9 - PubMed
  32. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S135-44 - PubMed
  33. Biochim Biophys Acta. 2010 Aug;1806(1):66-73 - PubMed
  34. Br J Cancer. 2010 Aug 24;103(5):663-7 - PubMed
  35. Curr Drug Targets. 2010 Aug;11(8):1000-17 - PubMed
  36. J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):431-41 - PubMed
  37. Cancer Res. 2001 Oct 1;61(19):7184-8 - PubMed
  38. Oncogene. 2000 Nov 16;19(48):5471-6 - PubMed
  39. J Biol Chem. 2010 Aug 20;285(34):26013-21 - PubMed
  40. J Biol Chem. 2002 Sep 13;277(37):34634-41 - PubMed
  41. J Cell Biol. 1994 Feb;124(4):619-26 - PubMed
  42. Lab Invest. 1995 Jan;72(1):55-63 - PubMed
  43. Cancer Res. 2007 May 1;67(9):4199-209 - PubMed
  44. Cell Cycle. 2010 Mar 15;9(6):1043-50 - PubMed
  45. Ann Oncol. 2007 Jun;18 Suppl 6:vi26-30 - PubMed
  46. Am J Pathol. 2009 Sep;175(3):1226-34 - PubMed
  47. Cell Cycle. 2005 Sep;4(9):1239-46 - PubMed
  48. Gastroenterology. 2011 Oct;141(4):1371-80, 1380.e1-2 - PubMed
  49. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24 - PubMed
  50. Br J Cancer. 2008 Oct 7;99(7):1089-95 - PubMed
  51. Oncogene. 1997 Sep 18;15(12):1497-502 - PubMed
  52. Int J Biochem Cell Biol. 2013 Dec;45(12):2832-42 - PubMed
  53. Adv Exp Med Biol. 2007;608:101-12 - PubMed
  54. Mol Cell Biol. 2004 Dec;24(24):10558-72 - PubMed
  55. Breast Cancer Res. 2007;9(6):R79 - PubMed
  56. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8443-8 - PubMed
  57. Oncologist. 2011;16 Suppl 1:12-9 - PubMed
  58. Blood Cells Mol Dis. 2007 Sep-Oct;39(2):212-20 - PubMed
  59. Cancer Res. 1992 Sep 1;52(17):4773-8 - PubMed
  60. Oncogene. 1997 Aug 14;15(7):799-805 - PubMed
  61. Genes Cancer. 2013 May;4(5-6):187-95 - PubMed
  62. Nat Rev Cancer. 2009 Jan;9(1):28-39 - PubMed
  63. Biochem J. 2012 Oct 15;447(2):313-20 - PubMed
  64. Anticancer Drugs. 2004 Feb;15(2):107-11 - PubMed
  65. Mol Cancer Res. 2013 Apr;11(4):381-92 - PubMed
  66. Arch Dermatol Res. 2011 May;303(4):293-7 - PubMed
  67. Physiol Genomics. 2012 Apr 15;44(8):455-69 - PubMed
  68. J Cell Sci. 2008 Aug 1;121(Pt 15):2435-44 - PubMed
  69. Oncologist. 2011;16(9):1203-14 - PubMed
  70. J Pathol. 2014 Jan;232(2):219-29 - PubMed
  71. J Cancer. 2011;2:324-8 - PubMed
  72. Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2359-64 - PubMed
  73. Br J Cancer. 1994 Aug;70(2):304-8 - PubMed
  74. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5870-5 - PubMed
  75. PLoS One. 2011 Mar 30;6(3):e14789 - PubMed
  76. Semin Oncol. 2002 Jun;29(3):231-45 - PubMed
  77. J Cell Sci. 2010 Jan 15;123(Pt 2):236-45 - PubMed
  78. Exp Cell Res. 1999 Nov 25;253(1):78-87 - PubMed
  79. Breast Cancer Res Treat. 2012 Jun;133(3):1049-56 - PubMed
  80. Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12463-8 - PubMed
  81. Mol Cancer Ther. 2007 Aug;6(8):2168-77 - PubMed
  82. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  83. Breast Cancer Res. 2013 Oct 01;15(5):R92 - PubMed
  84. Breast Cancer Res Treat. 2012 Jul;134(1):13-20 - PubMed
  85. J Biol Chem. 2004 Jul 9;279(28):29700-8 - PubMed
  86. J Pathol. 2005 Apr;205(5):592-6 - PubMed
  87. PLoS One. 2010 Jul 23;5(7):e11729 - PubMed
  88. J Biol Chem. 1996 Nov 29;271(48):30956-63 - PubMed
  89. Int J Cancer. 2010 Dec 1;127(11):2723-31 - PubMed
  90. Mol Cell Biol. 2006 Jul;26(13):4949-57 - PubMed
  91. Cancer Res. 2008 Jan 1;68(1):152-61 - PubMed
  92. Gastroenterology. 2009 Sep;137(3):945-54 - PubMed
  93. Front Biosci. 2008 May 01;13:3906-12 - PubMed
  94. Breast Cancer Res. 2011 Sep 17;13(5):R89 - PubMed

Publication Types